Ashkon Software



FLXN - Flexion Therapeutics, Inc.

Flexion Therapeutics, Inc. logo Flexion Therapeutics, Inc. (FLXN) is a biopharmaceutical company that develops and commercializes innovative therapies for the treatment of musculoskeletal conditions. The company's products and services include Zilretta, a non-opioid treatment for osteoarthritis knee pain, and FX301, a sustained-release local anesthetic for postoperative pain. Flexion Therapeutics is headquartered in Burlington, Massachusetts.

Flexion Therapeutics had a market capitalization of approximately $669 million. The company's total revenue for the fiscal year 2020 was $67.3 million, representing an increase from $51.3 million in the previous year. Net loss for the same period was $127.1 million, an increase from a net loss of $104.8 million in the previous year.

Flexion Therapeutics' products have the potential to address significant unmet medical needs in the treatment of musculoskeletal conditions. The company has a strong pipeline of product candidates, and has formed strategic partnerships with a range of organizations to expand the reach of its products and services.

The biopharmaceutical industry is subject to various risks, including regulatory risks and competition from other companies. However, Flexion Therapeutics' experienced management team, strategic partnerships, and strong pipeline of product candidates should position it well for continued success in the future.

Flexion Therapeutics' stock is listed on the NASDAQ stock exchange under the ticker symbol FLXN. Investors should carefully consider their investment objectives, risk tolerance, and other factors before investing in Flexion Therapeutics or any other biopharmaceutical




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer